Attached files
| file | filename |
|---|---|
| EX-99.3 - BIOMIMETIC THERAPEUTICS, INC. | v177133_ex99-3.htm |
| EX-99.2 - BIOMIMETIC THERAPEUTICS, INC. | v177133_ex99-2.htm |
| EX-99.1 - BIOMIMETIC THERAPEUTICS, INC. | v177133_ex99-1.htm |
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date of
Report (Date of earliest event reported): March 12, 2010 (March 11,
2010)
BIOMIMETIC
THERAPEUTICS, INC.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
000-51934
|
62-1786244
|
|
(State or other jurisdiction of
incorporation)
|
(Commission
File
Number)
|
(IRS Employer
Identification
No.)
|
389 Nichol Mill Lane,
Franklin, Tennessee 37067
(Address
of principal executive offices)
(615)
844-1280
(Registrant's
telephone number, including area code)
Not
Applicable
(Former
name, former address and former fiscal year,
if
changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
|
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Item
2.02 Results of Operations and Financial Condition.
On March
11, 2010, BioMimetic Therapeutics, Inc. (“BioMimetic”) issued a press release
that announced its financial results as of and for the three and twelve months
ended December 31, 2009. A copy of the press release is furnished as
Exhibit 99.1 to this Current Report on Form 8-K.
Item
8.01 Other Events.
On March 11, 2010, the lead
investigator for the Augment™ Bone Graft North American pivotal clinical trial,
Dr. Christopher DiGiovanni, Professor of Orthopaedic Surgery and Chief of Foot
and Ankle Surgery at The Warren Albert School of Medicine, presented additional
data from the pivotal trail at BioMimetic’s Annual Investor and Analyst Meeting
on March 11, 2010. The slides from that presentation are included as
Exhibit 99.2 to this Current Report on Form 8-K.
On March 11, 2010, Dr. Joshua S. Dines,
BioMimetic research collaborator and orthopedic surgeon, sports medicine and
shoulder service at The Hospital for Special Surgery in New York City, presented
newly released pre-clinical data at BioMimetic’s Annual Investor and Analyst
Meeting on March 11, 2010. The slides from that presentation are
included as Exhibit 99.3 to this Current Report on Form 8-K.
The
information in this Current Report on Form 8-K (including Exhibit 99.1, Exhibit
99.2 and Exhibit 99.3) shall not be deemed to be “filed” for purposes of Section
18 of the Securities and Exchange Act of 1934 (the Exchange “Act”) or otherwise
subject to the liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933 or the Exchange Act,
except as expressly set forth by specific reference in such a
filing.
Item
9.01 Financial Statements and Exhibits.
(d) Exhibits
99.1 Press
Release dated March 11, 2010
99.2 Augment™
Bone Graft presentation slides
99.3 Sports
Medicine presentation slides
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
|
BIOMIMETIC
THERAPEUTICS, INC.
|
|||
|
By:
|
/s/ Earl Douglas
|
||
|
Name:
|
Earl
Douglas
|
||
|
Title:
|
General
Counsel
|
||
Date: March
12, 2010